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Molecular genetic classiﬁcationThe neuronal ceroid-lipofuscinoses (Batten disease) collectively constitute one of the most common groups of
inherited childhood onset neurodegenerative disorders, and have also been identiﬁed in many domestic and
laboratory animals. The group of human neuronal ceroid-lipofuscinoses currently comprises 14 genetically
distinct disorders, mostly characterised by progressive mental, motor and visual deterioration with onset in
childhood or adolescence. Abnormal autoﬂuorescent, electron-dense granules accumulate in the cytoplasm
of nerve cells, and this storage process is associated with selective destruction and loss of neurons in the
brain and retina. The present paper outlines nearly 200 years of clinical, neuropathological, biochemical
and molecular genetic research, gradually leading, since 1995, to the identiﬁcation of 13 different genes
and over 360mutations that underlie these devastating brain disorders and form the basis of a new classiﬁcation
system. These genes are evidently of vital importance for the normal development and maintenance of cerebral
neurons. Elucidation of their functions and interactions in health and disease is a prerequisite for the identiﬁca-
tion of possible therapeutic targets, but may also further our understanding of the basic mechanisms of
neurodegeneration and ageing. An account is also given of the development of international cooperation and
free access electronic resources facilitating NCL research. This article is part of a Special Issue entitled:
The Neuronal Ceroid Lipofuscinoses or Batten Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The neuronal ceroid-lipofuscinoses (NCLs) [1,2] form a special
group within the inherited lysosomal storage disorders. They are also
collectively called Batten disease, according to the British neurologist
and neuropathologist Frederick Batten (1865–1918), an early pioneer
of the ﬁeld, who contributed to the identiﬁcation of two forms of NCL
(see Section 2). The NCLs have a worldwide distribution, but their inci-
dence rates may vary from 1:67000 in Italy and Germany to 1:14000 in
Iceland, and their prevalence rates from 1:1,000000 in some regions to
1:100000 in the Scandinavian countries [3]. A genetic founder effect is
well documented in some populations [3]. In addition to 14 genetically
distinct human NCLs so-far identiﬁed (Table 1), numerous spontaneous
forms of NCL have been discovered in domestic and laboratory animals.
Most human NCLs show an autosomal recessive mode of inheri-
tance, and may have variable ages of onset such as congenital, infantile,
late infantile, juvenile, adult or even late adult onset according to the
severity of mutation. The clinical characteristics of most childhood
forms include progressive loss of vision as well as mental and motorronal Ceroid Lipofuscinoses or
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rights reserved.deterioration, epileptic seizures and premature death, while the
rarer adult-onset forms are dominated by dementia.
Despite themolecular genetic and clinical differences, all forms of NCL
share unifying pathomorphological features. Autoﬂuorescent, electron-
dense, periodic acid-Schiff (PAS)- and Sudanblack B-positive granules, re-
sistant to lipid solvents, accumulate in the cytoplasm of most nerve cells
and, to a lesser extent, in many other cell types. In the brain, this storage
process is associated with progressive and selective loss of nerve cells. In
their distribution and physicochemical properties the NCL storage
granules bear close resemblance to lipofuscin, the “wear-and-tear
pigment”, accumulating in postmitotic cells during ageing.
Although the ﬁrst clinical description of possible cases of NCL
appeared as early as in 1826 [4], almost a century elapsed before subse-
quent papers were published, mostly under the generalised heading of
“amaurotic family idiocy”. The ﬁeld remained utterly confused until the
introduction of the NCL concept by Zeman and Dyken in 1969 [1]. The
present paper outlines nearly 200 years of NCL research, reviewing
the early clinical, neuropathological, and biochemical studies that
gradually led to the formulation of the NCL concept and deﬁnition of
the “classic” clinico-pathological entities. This early work was the pre-
requisite for the identiﬁcation, since 1995, of the responsible genomic
defects, now forming the basis of a new classiﬁcation system [2].
The NCL genes, many of them previously unknown, are evidently
of vital importance for the normal development and maintenance of
cerebral neurons. Elucidation of their speciﬁc functions and interac-
tions in health and disease is important for the identiﬁcation of
Table 1
Classiﬁcation and characteristics of human neuronal ceroid-lipofuscinoses (NCLs).
Disease Eponym OMIM
no.
Clinical phenotype Ultrastructure Gene Gene product Stored
protein
CLN1 Haltia–Santavuori 256730 Infantile classic, late infantile,
juvenile, adult
GRODs CLN1/
PPT1
PPT1 SAPs
CLN2 Janský–Bielschowsky 204500 Late infantile classic, juvenile CL CLN2/
TPP1
TPP1 SCMAS
CLN3 Spielmeyer-Sjögren 204200 Juvenile classic FP (CL, RL) CLN3 CLN3 SCMAS
CLN4 Parry 162350 Adult autosomal dominant GRODs CLN4/
DNAJC5
DNAJC5 SAPs
CLN5 Finnish variant late infantile 256731 Late infantile variant, juvenile, adult RL, CL, FP CLN5 CLN5 SCMAS
CLN6 Lake-Cavanagh early juvenile /Indian
variant late infantile, adult Kufs type A
601780 Late infantile variant, adult
(Kufs type A)
RL, CL, FP CLN6 CLN6 SCMAS
CLN7 Turkish variant late infantile 610951 Late infantile variant, juvenile, adult RL, FP CLN7/
MFSD8
MFSD8 SCMAS
CLN8 Northern epilepsy/progressive epilepsy
with mental retardation
610003 Late infantile variant, progressive
epilepsy with mental retardation
CL-like, FP
granular
CLN8 CLN8 SCMAS
CLN9 Juvenile variant 609055 Juvenile variant
CLN10 congenital 610127 Congenital classic, late infantile,
adult
GRODs CLN10/
CTSD
Cathepsin D SAPs
CLN11 Adult variant Adult FP CLN11/
GRN
Progranulin
CLN12 Juvenile variant Juvenile, Kufor-Raheb syndrome FP CLN12/
ATP13A2
P type ATPase
CLN13 Adult Kufs type B Adult Kufs type CLN13/
CTSF
Cathepsin F
CLN14 Infantile Infantile, progressive myoclonus
epilepsy 3
CLN14/
KCTD7
Potassium channel tetramerisation
domain-containing protein 7
GRODs, granular osmiophilic deposits; CL, curvilinear proﬁles; FP, ﬁngerprint bodies; RL, rectilinear proﬁles; SCMAS, subunit c of mitochondrial ATP synthase; SAPs, sphingolipid
activator proteins.
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of the basic mechanisms of neurodegeneration and ageing.
2. Early clinical and neuropathological studies of the NCLs
The ﬁrst clinical description of patients who may have suffered
from NCL [4] was published in 1826 by Dr. Otto Christian Stengel, a
general practitioner at the small copper-mining community of Røros
in South-Eastern Norway. During his long career he had observed a
“singular illness” affecting four children of a local family. The parents
were apparently healthy. By the age of 6 years, after unremarkable
early development, the sight of two sons and two daughters began
to deteriorate. Within years, the disease led to blindness, progressive
mental deterioration, loss of speech, and epileptic seizures. The two
oldest siblings had died by the age of 20 and 21 years [4]. No autopsies
were performed but, in retrospect, the clinical features are compatible
with CLN3 disease, classic juvenile. Unfortunately, Stengel's report,
written in Norwegian, remained unnoticed by the scientiﬁc community
until Nissen focused attention to its signiﬁcance in the 1950s [5].
By the end of the 19th century the American neurologist Sachs
formulated the inﬂuential concept of “amaurotic family idiocy”, based
on his observations in a set of siblings of rapidly progressive loss of vi-
sion and severe mental retardation of infantile onset [6]. At autopsy,
accumulation of material of lipid nature was observed within markedly
ballooned nerve cells of the brain. This disease, subsequently known as
Tay–Sachs disease, was later identiﬁed as GM2-gangliosidosis type A, a
prototype lysosomal storage disorder.
In the ﬁrst two decades of the 20th century a number of further
clinico-pathological studies of familial cases with progressive loss of
vision and psychomotor retardation were described, but many of
these had a later onset. Batten [7,8] and Vogt [9,10] reported patients
with both a late infantile and juvenile onset, while Spielmeyer
[11–13] described only individuals with a juvenile onset and Janský
[14] and Bielschowsky [15] patients with a late infantile onset. At
neuropathological investigation, all these patients with either late
infantile or juvenile onset of their disease showed intraneuronal accu-
mulation of granular material with lipid-like staining qualities. In their
early papers both Batten and Spielmeyer had distinguished their casesfrom those reported by Sachs. However, inspired by the superﬁcial
clinical similarities (familial occurrence, progressive loss of vision,
and psychomotor retardation) and the newly introduced unifying
pathological concept of intraneuronal “thesaurismosis” [16,17] or
“storage”, all these cases were gradually grouped together. They were
simply considered to represent variants of “amaurotic family idiocy”
of either infantile (Tay-Sachs), late infantile (Janský-Bielschowsky) or
juvenile (Spielmeyer-Sjögren) onset. In 1925 Kufs published his ﬁrst re-
port [18] on adult onsetmental deteriorationwith similar intraneuronal
storage but without evident loss of vision.
3. The NCL concept and clinico-pathological classiﬁcation of the NCLs
In the 1930s two studies were publishedwhich began to undermine
the validity of the prevailing unitarian view of the “amaurotic family
idiocies”. Sjögren [19] carried out extensive clinical and genealogical
studies of patients with “juvenile amaurotic idiocy” and their families in
Southern Sweden. Based on statistical analyses of about 4500 members
of affected families he concluded that “juvenile amaurotic idiocy” showed,
with high probability, a “monohybrid recessive inheritance”, and was
genetically distinct from “infantile amaurotic idiocy” (Tay–Sachs disease).
A further argument against the unitarian view was provided by
Klenk [20] who demonstrated an increased cerebral ganglioside con-
centration in the infantile form (Tay–Sachs) but not in the juvenile type
(Spielmeyer–Sjögren). Klenk's ﬁndings were later conﬁrmed by
Svennerholm [21] in 1962 who ﬁnally identiﬁed the major storage ma-
terial in the infantile form (Tay–Sachs) as GM2-ganglioside.
The ﬁnal blow to the unitarian view came, however, through the
histochemical and electron microscopic studies of Zeman and his
collaborators in the 1960s. They showed [22] that the intraneuronal
storage cytosomes in the late infantile (Janský–Bielschowsky) and
juvenile (Spielmeyer–Sjögren) forms of “amaurotic idiocy” radically
differed from the membraneous cytoplasmic bodies described in the
infantile form (Tay–Sachs) by Terry and Korey [23]. While the storage
material in the infantile Tay–Sachs form was easily extractable, the
autoﬂuorescent andelectron-dense storage cytosomes in the late infantile
(Janský–Bielschowsky) and juvenile (Spielmeyer–Sjögren) forms
were largely resistant to lipid solvents, and showed characteristic
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(Spielmeyer–Sjögren) ultrastructural patterns [22,24]. These character-
istics and the distribution of the storage materials bore a striking resem-
blance to the autoﬂuorescent “lipopigments” ceroid or lipofuscin. Based
on this resemblance, in 1969 Zeman and Dyken proposed the new
term neuronal ceroid-lipofuscinosis (NCL) [1], in order to clearly distin-
guish the late infantile and juvenile forms of “amaurotic family idiocy”
and the histochemically similar adult onset cases reported by Kufs
from Tay–Sachs disease and other gangliosidoses.
A new infantile type of NCL was soon described by Haltia and
Santavuori and their collaborators [25–28]. This diseasewas characterised
by autoﬂuorescent electron-dense storage cytosomeswith a ﬁnely granu-
lar ultrastructure (granular osmiophilic deposits or GRODs). Furthermore,
the ﬁrst animal form of NCL was reported in English setter dogs by
Koppang [29].
In 1976 Zeman [30] proposed a classiﬁcation of the NCLs, essentially
based on the age of clinical onset and the ultrastructure of the storage
cytosomes. He distinguished four different human and one canine form
of NCL. The NCLs thus included the human infantile (Haltia–Santavuori),
late infantile (Janský–Bielschowsky), juvenile (Spielmeyer–Sjögren),
and adult (Kufs) types, and the canine form in English setters described
by Koppang.
4. Expansion of the NCL family
In his classiﬁcation in 1976 Zeman [30] had not taken into consider-
ation the occasional cases of congenital “amaurotic family idiocy”,
reported since 1941 [31–33]. Furthermore, since the end of the 1970s,
a number of “atypical” or “variant” cases of NCL were reported, many
of them with a late infantile or early juvenile onset. These included
what were described as “early juvenile”, “Czech” or “Indian” [34,35],
“Finnish” [36–38], and “Turkish” [39] variant late infantile forms of
NCL. Interestingly, even “Northern epilepsy” or progressive epilepsy
with mental retardation [40] later turned out to be a member of the
NCL category at neuropathological analysis [41,42], although it had
originally been conceived as an inherited childhood epilepsy syndrome
with relatively mild mental retardation. While autosomal recessive in-
heritance is the rule in the various forms of NCL, there were also a few
reports of autosomal dominant adult onset NCL [43,44].
In addition to the expansion of the category of human NCLs, an in-
creasing number of spontaneous forms of NCL were discovered in
domestic and laboratory animals. Various forms of NCL were reported
in many breeds of dogs [see 45], cats [46–49], sheep [50–52], goats
[53], cattle [54,55], horses [56], and mice [57,58].
5. Biochemical studies of the NCLs
As indicated before, by the end of the 1930s Klenk [20] had biochem-
ically distinguished “juvenile amaurotic idiocy” (Spielmeyer–Sjögren)
from “infantile amaurotic idiocy” (Tay–Sachs), demonstrating cerebral
ganglioside accumulation only in the latter, a ﬁnding conﬁrmed by
Svennerholm in 1962 [21]. In the 1970s and 1980s progress was
hampered by the fallible peroxidation hypothesis (see Section 7).
Important new information was ﬁrst gained by biochemical analyses
of the South Hampshire sheep model of NCL by the end of the 1980s.
Palmer et al. [59] were able to solubilise the ovine storage material,
showing that it was composed of discrete chemical species, i.e. phos-
pholipids, neutral lipids, dolichols and proteins. The major component
of the isolated storage cytosomes was low-molecular-weight protein
[59], soon identiﬁed as subunit c of mitochondrial ATP synthase
[60,61]. Subsequently, this mitochondrial protein was also found to be
the predominant constituent of the storage cytosomes in most other
human and animal forms of NCL [62]. However, corresponding protein
chemical analyses of isolated storage bodies in the human infantile NCL
disclosed sphingolipid activator proteins (saposins) A and D as their
main components [63]. Later, accumulation of sphingolipid activatorproteins was also observed in the miniature Schnautzer dog model of
NCL [64], congenital ovine NCL [65], congenital human NCL [66], and
the autosomal dominant form of adult human NCL or Parry disease
[44]. The various human and animal forms of NCL can thus be grouped
into two main categories: those predominantly storing subunit c of the
mitochondrial ATP synthase, and those accumulating sphingolipid
activator proteins A and D. Interestingly, the ultrastructure of the storage
cytosomes seems to be related to their main protein component. Accu-
mulation of sphingolipid activator proteins has invariably been associated
with GRODs, while storage of subunit c of mitochondrial ATP synthase
has been linked with membrane-like structures of curvilinear, rectilinear
or ﬁngerprint patterns. It is worthy of note that mutations in genes
encoding SCMAS and SAPs have not yet been identiﬁed in the NCLs.6. Molecular genetic studies and genetics-based classiﬁcations of
the NCLs
The juvenile Spielmeyer–Sjögren type of NCL was linked to the
haptoglobin locus on the long arm of chromosome 16 in 1989 [67]. How-
ever, the ﬁrst NCL gene, responsible for the infantile Haltia–Santavuori
form of NCL, was identiﬁed by a positional candidate gene approach in
1995 in Leena Peltonen's laboratory [68]. This gene encodes palmitoyl
protein thioesterase 1 (PPT1), a soluble lysosomal enzyme. Later in the
very same year, the combined effort of an international consortium of
ﬁve research groups led to the isolation, by positional cloning, of the
gene underlying the juvenile Spielmeyer–Sjögren type of NCL [69]. This
novel gene encodes a membrane protein [70]. Since 1995 more than
ten further genes (see Table 1) and a continuously increasing num-
ber of mutations (>360) [71] responsible for established human
forms of NCL have been identiﬁed, now listed in a mutation database
at www.ucl.ac.uk/ncl, maintained by Dr. Sara Mole at University
College London.
By the turn of the millennium, progress was also made in the
study of the primary genomic defects in spontaneous animal forms
of NCL. With one exception, all the NCL genes so far isolated in ani-
mals have turned out to be homologues of previously established
human NCL genes. A new NCL gene was discovered in congenital
ovine NCL by a protein chemical approach. The affected lambs had
drastically reduced activity of the soluble lysosomal hydrolase ca-
thepsin D, caused by a mutation of the ovine CTSD gene [65]. A ca-
thepsin D-deﬁcient Drosophila model recapitulated the key features
of NCL [72]. Starting from these observations in lambs and ﬂies, ca-
thepsin D deﬁciency was ﬁnally shown to underlie even congenital
human NCL [66] (Table 1).
Zeman's classiﬁcation of the NCLs in 1976 [30] was based on their
clinical and neuropathological phenotypes, mainly on the age of onset
of the clinical manifestations and ultrastructure of the storage
cytosomes. The advances in molecular genetics made this old classiﬁ-
cation problematic. Different mutations in a given gene may give rise
to varying phenotypes, including widely different ages of onset. For
example, mutations of the CLN1 gene may result in disease with an in-
fantile, late-infantile, juvenile, or even adult onset, depending on the
exact type and location of the mutation in relation to the active site of
the gene product. Consequently, a new purely genetic classiﬁcation of
the NCLs evolved, based on veriﬁed or predicted gene loci [73]. At the
moment, the human NCLs are classiﬁed into 14 genetic forms from
CLN1 to CLN14 (Table 1) [74,75].
More recently, an international group of physicians and scientists
proposed and evaluated a new diagnostic classiﬁcation system and
nomenclature of the NCLs to provide a deﬁnition for NCL subtypes
that is universally understood and of value for clinicians responsible
for diagnosis and treatment, research scientists, patients and families
[76–78]. This axial system derives from the primary genetic defect and
takes into account varying phenotype, e.g. “CLN1 disease, infantile”, or
“CLN1 disease, adult” (Table 1).
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The ﬁrst pathogenetic hypothesis on the NCLs was put forward in
1975 [79], after their separation from Tay–Sachs disease and other
gangliosidoses. It was inspired by the physicochemical resemblance of
the storage materials to the “wear and tear lipopigments” lipofuscin
or its pathological counterpart ceroid [1]. Lipofuscin granules had
been ﬁrst described in the cytoplasm of nerve cells by Hannover in
1843 [80], and Hueck [81] had concluded that “das fetthaltige
Abnutzungspigment” might form by oxidation of fatty acids. Zeman
and Rider now hypothesised that the basic defect in the NCLs was for-
mation of pathological “lipopigments”, possibly due to an increased
rate of peroxidation of polyunsaturated fatty acids [79]. However, de-
spite numerous experimental and clinical studies, including treatment
of patients with various antioxidants, no conclusive evidence could be
presented in favour of this idea.
Since 1995, molecular genetic studies have identiﬁed over 360
mutations in 13 different genes underlying the various established
human forms of NCL [71]. The NCL genes are evidently of vital impor-
tance for the normal development andmaintenance of cerebral neurons.
Four of these genes code for soluble lysosomal enzymes, whereas the
products of several of the remaining genes are putative transmembrane
proteins with still largely unknown functions (Table 1). This impressive
set of newmolecular data provides a solid foundation, and the numerous
available spontaneous or genetically manipulated models [2] efﬁcient
tools, for studies aiming at ﬁlling the gap between the primary genomic
defects and the ﬁnal neuropathological and clinical manifestations of the
NCLs.
Interestingly, the striking molecular genetic heterogeneity of the
NCLs is in sharp contrast to their remarkably uniform morphological
phenotype, the very basis of the whole NCL concept [82,83]. All
forms of NCL share at least two essential features: 1) accumulation in
the lysosomes of nerve cells and, to a lesser extent, of many other cell
types, of autoﬂuorescent, electron-dense, PAS- and Sudan black
B-positive material containing subunit c of mitochondrial ATP synthase
and/or sphingolipid activator proteins A and D, and 2) progressive and
selective loss of neurons, particularly in the cerebral and cerebellar cor-
tex and, less constantly, in the retina, leading tomental, motor and visu-
al deterioration. Any valid theory on the pathogenesis of the NCLs must
account for these two phenomena and explain them at the molecular
level [82,83]. Elucidation of the pathogenetic mechanisms of the NCLs
may not only indicate molecular targets for rational therapies but also
deepen our understanding of ageing and neurodegenerative pathways
in general. It should not be forgotten that the time-dependent accumula-
tion of lipofuscin in lysosomes of postmitotic cells is considered the most
consistent and phylogenetically constantmorphological change of ageing
[84].
8. International collaboration and electronic resources in
NCL research
The remarkable acceleration of research on the NCLs during the past
few decades would not have been possible without extensive interna-
tional collaboration between clinicians, neuropathologists, biochemists,
geneticists, andmolecular biologists. This collaboration has been greatly
facilitated by the support of a number of private and public initiatives
and organisations [see 85].
The Children's Brain Diseases Foundation, established by Dr. J. Alfred
Rider, San Francisco, USA, sponsored a series of six “round table” confer-
ences on the pathogenesis of theNCLs in 1969–1975 [79]. Thesemeetings
were followed in 1980 by the ﬁrst International Symposium on Human
and Animal Models of Ceroid-Lipofuscinosis in Røros, Norway [86], and
since 1987, by the International Conferences/Congresses on the NCLs,
held at 2–3- year intervals in the USA or different European countries.
A European Concerted Action “Molecular, pathological and clinical
investigations of neuronal ceroid-lipofuscinoses (NCL) — new strategiesfor prevention, diagnosis, classiﬁcation and treatment” (ECA-NCL) was
initiated and coordinated by ProfessorHansH. Goebel ofMainz, Germany,
as part of the BIOMED 2 programme of the European Union. ECA-NCL
integrated the NCL-related work of 25 European research groups,
starting a series of regular meetings in Helsinki in 1996. ECA-NCL
established the European clinical and tissue registries and produced
the ﬁrst edition of the handbook “The Neuronal Ceroid Lipofuscinoses
(Batten Disease)” [73].
As mentioned before, the accelerating pace of discovery of new
NCL-related genes and mutations prompted the establishment, in
1998, of an electronic NCL Mutation Database, maintained by Dr. Sara
Mole at University College London. The database is now part of the
“NCL Resource — a gateway for Batten disease” (http://www.ucl.ac.
uk./ncl/index.shtml), providing up-to-date information on the NCLs
for clinicians, families and researchers on a free access basis. The most
recent developments include the establishment of the “Rare NCL Gene
Consortium”, coordinated by Dr. Sara Mole with participants from
Europe and the USA, and a web-based NCL Registry, spearheaded
by Professor Alfried Kohlschütter and Dr. Angela Schultz, Hamburg,
Germany. In the USA the longstanding Batten Disease Support and
Research Association supports similar activities, including DNA and
cell banks. There are also disease-rating scales for juvenile and late
infantile NCL, long established in Europe and more recently the USA.
The active collaboration of the patients families and their organisa-
tionswith theNCL research community has been invaluable in promoting
both research and the rapid and efﬁcient transfer of the newest scientiﬁc
information to daily diagnostic and therapeutic practice for the beneﬁt of
the affected individuals. These increasingly professional family-led orga-
nisations have been leading theway in coordinating family support with-
in their country as well as directing the funding of research, and several
are now working together as the Batten Disease International Alliance.
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